Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552730 · ClinicalTrials.gov registry record
Nerve Growth Factor for the Treatment of Cornea Disease
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 5
- Enrollment target
NCT04552730: Completed study, sponsored by Stanford University.
NCT04552730 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552730 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
Primary Outcome
Change in size of abnormal epithelium compared to baseline
Interventions
- DRUG Cenegermin-Bkbj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2021-05-04 |
What the finished NCT04552730 record still lists
NCT04552730 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cenegermin-Bkbj is the first listed.
NCT04552730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04552730 about?
NCT04552730 is a clinical study titled "Nerve Growth Factor for the Treatment of Cornea Disease". To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
What is the current status of trial NCT04552730?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2020-10-14. Estimated completion is 2021-05-04.
What interventions are being tested in trial NCT04552730?
The interventions under investigation include: Cenegermin-Bkbj (DRUG).
Who is sponsoring clinical trial NCT04552730?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI